About Clovis

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets.

Building on its core competencies in clinical development, regulatory affairs and commercialization of innovative anti-cancer agents, Clovis intends to license or acquire rights to oncology compounds in all stages of clinical development.

Clovis intends to target development programs at specific subsets of cancer populations, and will simultaneously develop diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use.

In May 2009, the Company announced that it had secured $146 million in start-up financing. Investors in Clovis include Domain Associates, New Enterprise Associates (NEA), Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures, ProQuest Investments and the Company’s management team.The Company was founded by former executives of Pharmion Corporation, which was acquired by Celgene Corporation in 2008.

In November 2009, Clovis licensed the development and commercialization rights to its first oncology product candidate, CO-101 (formerly developed by Clavis Pharma as CP-4126), currently in Phase 2 development for pancreatic cancer. CO-101 is a novel, patented, lipid-conjugated form of the anti-cancer drug gemcitabine that has the potential to improve treatment outcomes in a large subset of patients with pancreatic cancer and certain other solid tumors.

The Company is headquartered in Boulder, Colorado, and has additional offices in San Francisco and London.